Market Place
Sourcing Support
Lipocine Publishes LPCN 1148 Data at The Liver Meeting 2024
18 Nov 2024 //
PR NEWSWIRE
Lipocine Announces Q3 2024 Financial Results
07 Nov 2024 //
PR NEWSWIRE
Lipocine Signs Distribution Deal for TLANDO® in South Korea
31 Oct 2024 //
PR NEWSWIRE
Lipocine Enters Supply And Distribution Deal With Pharmalink
10 Oct 2024 //
CONTRACT PHARMA
Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results
10 Oct 2024 //
PR NEWSWIRE
Lipocine Announces Supply And Distribution Agreement With Pharmalink
08 Oct 2024 //
PR NEWSWIRE
Lipocine To Present At HC Wainwright 8th Annual MASH Conference
30 Sep 2024 //
PR NEWSWIRE
Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®
05 Sep 2024 //
PR NEWSWIRE
Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference
27 Aug 2024 //
PR NEWSWIRE
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024
08 Aug 2024 //
PR NEWSWIRE
Lipocine Presents 52-Week LPCN 1148 Phase 2 Data At EASL 2024
10 Jun 2024 //
PR NEWSWIRE
Lipocine Presents LPCN 1148 Phase 2 Data At EASL Congress 2024
08 May 2024 //
PR NEWSWIRE
Lipocine Completes Dosing In LPCN 1154 Postpartum Depression Study
01 May 2024 //
PR NEWSWIRE
Lipocine Announces Positive LPCN 2401 Clinical Results
12 Apr 2024 //
BIOSPACE
Lipocine`s LPCN 2401 Improves Body Composition In Obesity
11 Apr 2024 //
PR NEWSWIRE
Lipocine Announces Positive Data from Ph 2 Study in Patients with Cirrhosis
28 Mar 2024 //
PR NEWSWIRE
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
25 Mar 2024 //
PR NEWSWIRE
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
07 Mar 2024 //
PR NEWSWIRE
Lipocine to Present at 36th Annual Roth Conference
06 Mar 2024 //
PR NEWSWIRE
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154
06 Feb 2024 //
PR NEWSWIRE
Lipocine Announces Continued Commercialization of TLANDO® through Verity
02 Feb 2024 //
PR NEWSWIRE
Lipocine and Verity Pharma Enter into License Agreement
18 Jan 2024 //
PR NEWSWIRE
Lipocine to Present at Biotech Showcase 2024
19 Dec 2023 //
PR NEWSWIRE
Lipocine Completes Meeting with FDA on LPCN 1154 in Postpartum Depression
26 Oct 2023 //
PR NEWSWIRE
LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis
27 Jul 2023 //
PR NEWSWIRE
Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference
14 Jun 2023 //
PR NEWSWIRE
Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023
07 Jun 2023 //
PR NEWSWIRE
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023
11 May 2023 //
PR NEWSWIRE
First Subject Dosed in Bridge Study with Lipocine Depression Candidate,LPCN 1154
03 Apr 2023 //
PR NEWSWIRE
Lipocine Announces Financial Results for the Year Ended December 31, 2022
10 Mar 2023 //
PR NEWSWIRE
Lipocine Completes Enrollment of LPCN 1148 PII Study for Decompensated Cirrhosis
19 Dec 2022 //
PRNEWSWIRE
Lipocine Announces Senior Leadership Appointments to Advance its CNS-Focused
03 Nov 2022 //
BIOSPACE
Lipocine Announces Realignment and Forward Focus on Treating CNS Disorders
26 Sep 2022 //
PRNEWSWIRE
Lipocine seeks partner for NASH asset in pivot to oral CNS drugs
26 Sep 2022 //
FIERCEPHARMA
Lipocine Announces Regulatory Pathway on Oral LPCN 1154 for PPD
15 Sep 2022 //
PRNEWSWIRE
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2022
08 Aug 2022 //
PRNEWSWIRE
Lipocine to commence Phase II epilepsy treatment trial
12 Jul 2022 //
CLINICALTRIALSARENA
FDA Clears LPCN 2101 IND for Adult Epilepsy Treatment
11 Jul 2022 //
PRNEWSWIRE
Lipocine Granted US Patents Directed To CNS And Liver Programs
14 Jun 2022 //
PRNEWSWIRE
Lipocine Announces Presentation At 2022 Epilepsy Foundation Pipeline Conference
06 Jun 2022 //
PRNEWSWIRE
Lipocine Announces Positive LPCN 1144 NASH Open Label Extension Study Results
12 May 2022 //
PRNEWSWIRE
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2022
09 May 2022 //
PRNEWSWIRE
LIPOCINE ANNOUNCES BOARD of DIRECTOR APPOINTMENTS
11 Apr 2022 //
PRNEWSWIRE
LIPOCINE ANNOUNCES ITS PARTNER RECEIVED FDA APPROVAL OF TLANDO
29 Mar 2022 //
PRNEWSWIRE
Lipocine Announces Financial Results for the Year Ended December 31, 2021
09 Mar 2022 //
PRNEWSWIRE
Lipocine`s Partner Received FDA Acceptance Of NDA Resubmission For Tlando
03 Feb 2022 //
PRNEWSWIRE
Lipocine Announces Peer-Reviewed Publication of Phase 3 Study Results for TLANDO
27 Jan 2022 //
PRNEWSWIRE
Lipocine Announces Financial Results for Q3 Ended September 30, 2021
10 Nov 2021 //
PRNEWSWIRE
Lipocine Announces FDA Grants Fast Track Designation to LPCN 1144
04 Nov 2021 //
PRNEWSWIRE
Lipocine Announces Multiple Poster Presentations at the American Association
01 Nov 2021 //
PRNEWSWIRE
Antares Pharma Enters into Exclusive License Agreement With Lipocine TLANDO®
18 Oct 2021 //
GLOBENEWSWIRE
Lipocine and Antares Pharma enter agreement to commercialise TLANDO®
18 Oct 2021 //
PHARMAFILE
Lipocine to Present at The H.C. Wainwright 5th Annual NASH Investor Conference
05 Oct 2021 //
PRNEWSWIRE
Lipocine`s LPCN 1144 Met NASH Resolution Regulatory Endpoint in Phase 2 Study
25 Aug 2021 //
PRNEWSWIRE
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2021
05 Aug 2021 //
PRNEWSWIRE
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2021
05 Aug 2021 //
PRNEWSWIRE
Lipocine Announces Settlement With Clarus Therapeutics
14 Jul 2021 //
PRNEWSWIRE
Lipocine Announces Settlement With Clarus Therapeutics
14 Jul 2021 //
PRNEWSWIRE
Lipocine To Present At The Ladenburg Thalmann Healthcare Conference
07 Jul 2021 //
PR NEWSWIRE
Lipocine To Present At The Ladenburg Thalmann Healthcare Conference
07 Jul 2021 //
PR NEWSWIRE
